en · de · es
sr9009-notes.peptides1004.com › News › Sr9009 Identity And Mechanism — Reference Sheet

Sr9009 Identity And Mechanism — Reference Sheet

By Editorial Desk · published 2025-10-19 · last reviewed 2025-11-19 · News

This is a working overview of HPLC-UV, written for readers who want more than a one-paragraph summary but less than a textbook.

Reviewed 2025-11-19. Anything still debated is marked as such rather than presented as settled.

SR9009 Identity and Mechanism

SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.

SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.

REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.

Handling Storage and Quality Control

Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.

Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.

Sr9009 at a glance

PropertyValueNotes
Common nameSR9009Also marketed informally as Stenabolic
Chemical classSynthetic REV-ERB agonistBinds REV-ERBα and REV-ERBβ
Molecular formulaC24H30ClN3O4SApproximate molecular weight 492 g/mol
CAS Registry Number1379686-30-2Identifier for the parent compound
Regulatory statusNot approved for human useProhibited in sport by WADA

Mechanism and Preclinical Findings

The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.

SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.

Related pages on this site

Identity, Handling, and Regulation

Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.

In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.

Background from the literature

== Importance == Penicillium expansum produces the mycotoxin patulin, a neurotoxin that can enter the food supply via apples and apple products such as juice and cider. Considering the size of the apple product industry and the large number of people that may come into contact with infected fruits, control of P. expansum is vitally important.

=== Differential diagnoses === The muscle weakness that worsens with activity (abnormal muscle fatigue) in myasthenia gravis is a symptom shared by other neuromuscular diseases. Most of the metabolic myopathies, such as McArdle disease (GSD-V), have abnormal muscle fatigue rather than fixed muscle weakness. Also, like myasthenia gravis, exercise intolerance in McArdle disease improves with regular physical activity (performed safely using activity adaptations such as getting into second wind, the "30 for 80 rule," and "six second rule"). A small minority of people with McArdle disease also have the comorbidity of ptosis (drooping upper eyelid). Late-onset GSD-II (Pompe disease) and GSD-XV also have muscle weakness or fatigue with comorbidities of ptosis and ophthalmoplegia; as do many of the mitochondrial myopathies. Other diseases that involve abnormal muscle fatigue (which may be described as exercise-induced muscle weakness, reversible muscle weakness, or muscle weakness that improves with rest) include: endocrine myopathies (such as Hoffman syndrome), Tubular aggregate myopathy (TAM), ischemia (such as intermittent claudication, popliteal artery entrapment syndrome, and chronic venous insufficiency), and poor diet or malabsorption diseases that lead to vitamin D deficiency (osteomalic myopathy). Although limb-girdle muscular dystrophies (LGMDs) involve fixed muscle weakness, LGMDR8 also involves muscle fatigue; as do some limb-girdle muscular dystrophy-dystroglycanopathies such as MDDGC3 (a.k.a. LGMDR15 and LGMD2O).

1993/150) Council Tax (Liability for Owners) (Amendment) Regulations 1993 (S.I. 1993/151) Genetically Modified Organisms (Deliberate Release) Regulationa 1993 (S.I. 1993/152) Barnsley Community and Priority Services National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/153) Mersey Regional Ambulance Service National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/154) North Mersey Community National Health Service Trust (Establishment) Amendment Order 1993 (S.I. 1993/155) Shropshire's Mental Health National Health Service Trust (Establishment) Amendment Order 1993 (S.I. 1993/156) Thameside Community Health Care National Health Service Trust (Change of Name) Order 1993 (S.I. 1993/157) Drivers' Hours (Passenger and Goods Vehicles) (Exemption) (Revocation) Regulations 1993 (S.I. 1993/158) Manchester Central Hospitals and Community Care National Health Service Trust (Change of Name) Order 1993 (S.I. 1993/159) A30 and A39 Trunk Roads (Indian Queens, Fraddon and St Columb Road Bypasses and Slip Roads) Order 1993 (S.I. 1993/163) A30 and A39 Trunk Roads (Indian Queens, Fraddon and St Columb Road Bypasses) (Detrunking) Order 1993 (S.I. 1993/164) General Drainage Charges (Relevant Quotient) Regulations 1993 (S.I. 1993/165) Central Rating Lists (Amendment) Regulations 1993 (S.I. 1993/166) Spring Traps Approval (Scotland) Variation Order 1993 (S.I. 1993/167) Humberside and South Yorkshire (County Boundaries) Order 1993 (S.I. 1993/168) Special Road Schemes and Highways Orders (Procedure) Regulations 1993 (S.I.

== Function == Citrulline is a metabolic intermediate within the urea cycle, which is the pathway by which mammals excrete ammonia by converting it into urea. Citrulline is also produced as a byproduct of the enzymatic production of nitric oxide from the amino acid arginine, catalyzed by nitric oxide synthase. In the yeast species Saccharomyces cerevisiae, citrulline is a metabolic intermediate in the latter, cytosolic half of the arginine biosynthesis pathway. Several proteins contain citrulline as a result of a post-translational modification. These citrulline residues are generated by a family of enzymes called peptidylarginine deiminases, which convert arginine into citrulline in a process called citrullination or deimination with the help of calcium ions. Proteins that normally contain citrulline residues include myelin basic protein, filaggrin, and several histone proteins, whereas other proteins, such as fibrin and vimentin are susceptible to citrullination during cell death and tissue inflammation. Circulating citrulline concentration is a biomarker of intestinal functionality.

Sources: en.wikipedia.org

Further detail

=== Radioactive isotopes === The existence of isotopes was first suggested in 1913 by the radiochemist Frederick Soddy, based on studies of radioactive decay chains that indicated about 40 different species referred to as radioelements (i.e. radioactive elements) between uranium and lead, although the periodic table only allowed for 11 elements between lead and uranium inclusive. Several attempts to separate these new radioelements chemically had failed. For example, Soddy had shown in 1910 that mesothorium (later shown to be 228Ra), radium (226Ra, the longest-lived isotope), and thorium X (224Ra) are impossible to separate. Attempts to place the radioelements in the periodic table led Soddy and Kazimierz Fajans independently to propose their radioactive displacement law in 1913, to the effect that alpha decay produced an element two places to the left in the periodic table, whereas beta decay emission produced an element one place to the right. Soddy recognized that emission of an alpha particle followed by two beta particles led to the formation of an element chemically identical to the initial element but with a mass four units lighter and with different radioactive properties. Soddy proposed that several types of atoms (differing in radioactive properties) could occupy the same place in the table. For example, the alpha-decay of uranium-235 forms thorium-231, whereas the beta decay of actinium-230 forms thorium-230.

Market Place (formerly Market Place by Jasons, Jason's Food & Living, and Jasons ichiba) in Hong Kong is a high-end supermarket chain owned by DFI Retail Group. The chain also has a joint venture in mainland China with Beijing Hualian Group called BHG Market Place and formerly ran stores (Jasons Market Place) in Taiwan until they were sold to Carrefour. The Malaysian chain called Mercató (formerly Jasons Food Hall) is owned by Macrovalue Sdn Bhd. after its acquisition of DFI Malaysian food retailing business in 2023. Cold Storage Fresh (formerly Market Place, Jasons, and Jasons Deli) in Singapore is also owned by Macrovalue Sdn Bhd since 2025. The Marketplace (formerly Market Place by Rustan's) in the Philippines has been owned by Robinsons Retail Holdings since 2018, before which it was owned by Rustan Supercenters. DFI also operates further similar supermarkets under the 3hreeSixty and Oliver's The Delicatessen brands in Hong Kong and other supermarkets around Asia with Wellcome.

== Preservation of other products == Water-based home and personal care products use broad-spectrum preservatives, such as isothiazolinones and formaldehyde releasers, which may cause sensitization, leading to allergic skin.

In Japan, labeling guidelines introduced in 2007 recommend that the designation Wagyu be used only for beef from cattle documented as one of the four breeds or specified crosses between them and confirmed as having been born and raised in Japan. Beginning in the 1970s, cattle and genetic material exported from Japan formed the basis of Wagyu herds in the United States and Australia. Breed associations in both countries maintain their own herdbooks and DNA-based parentage-verification systems, registering cattle according to their documented pedigree and proportion of Wagyu ancestry.

=== Synonyms === In 1838, Cantor proposed the name Hamadryas ophiophagus for the king cobra and explained that it has dental features intermediate between the genera Naja and Bungarus. Naia vittata proposed by Walter Elliot in 1840 was a king cobra caught offshore near Chennai that was floating in a basket. This provenance is disputed, as wild king cobras have never occurred near Chennai, and an analysis of this specimen has found it to be more similar to the northern king cobra. Hamadryas elaps proposed by Albert Günther in 1858 were king cobra specimens from the Philippines and Borneo. Günther considered both N. bungarus and N. vittata a variety of H. elaps. Naja ingens proposed by Alexander Willem Michiel van Hasselt in 1882 was a king cobra captured near Tebing Tinggi in northern Sumatra. The earliest scientific name for the king cobra was Naja bungaroides, given by Friedrich Boie in 1828 based on a juvenile specimen from Java. This description was improperly done, leaving it a nomen nudum at the time. However, Johann Georg Wagler validated the name in 1830 with a sufficient diagnosis, and also proposed a new genus for it, Hoplocephalus. In 1837, Hermann Schlegel used the name Naja bungaroides for his description of the Australian broad-headed snake, which was later reclassified into Wagler's Hoplocephalus, and used the species name Naja bungarus for the king cobra.

Sources: en.wikipedia.org

Supporting material

As of April 2024, the flow of cash from Novo's weight-loss drugs was continuing to solidify its status as the most valuable company in Europe, to the point that economists were worried that Denmark might come down with Dutch disease (that is, a country that does only one thing well and nothing else). The company's market capitalization of $570 billion remained larger than the entire economy of Denmark, its $2.3 billion income tax bill for 2023 made it the largest taxpayer in the country, and its rapid growth was driving nearly all of the expansion of Denmark's economy. The company had started to move away from its traditional focus on diabetes care towards a more ambitious mission to "defeat serious chronic diseases", and towards that end, hired over 10,000 people in 2023 alone. To effectively manage the rapid expansion of its workforce while maintaining its traditional corporate culture, the Novo Nordisk Way, the company put over 400 senior executives through a leadership development program called NNX, which stands for Novo Nordisk Next. In May 2024, the company announced it would acquire Austrian fluid management service business, Single Use Support. In June 2024, the company announced plans to build a new production plant in Clayton, North Carolina, at a cost of $4.1 billion. It will be the company's fourth in the state of North Carolina and used for production of semaglutide products Ozempic and Wegovy. The company also announced plans to acquire three US-based Catalent sites in to increase production supply.

This end proves to be both more thermodynamically favored for the addition of G-actin and kinetically dynamic as well. Simultaneously, older G-actin monomers "fall off" of the pointed end of the microfilament. At the "pointed end" of the F-actin polymer, actin monomers are bound to ADP, which dissociates more readily and rapidly than ATP-bound actin, which is found at the "barbed end" of the polymer. Thus, in environments with high concentrations of free actin subunits, filamentous growth at the "barbed end" remains greater than that of the "pointed end". This "tread-milling", essentially exists as a simplified explanation of the actin remodeling process.

Fluorocarbons and Sulphur Hexafluoride, proposed by the European Fluorocarbons Technical Committee CFCs and Ozone Depletion Freeview video provided by the Vega Science Trust. Introduction to fluoropolymers Organofluorine chemistry by Graham Sandford

=== Characteristics in patients === There is a relationship between the subcutaneous dose of calcitonin and peak plasma concentrations. Following parenteral administration of 100 IU calcitonin, peak plasma concentration lies between about 200 and 400 pg/ml. Higher blood levels may be associated with increased incidence of nausea, vomiting, and secretory diarrhea.

Most vertebrates are plantigrade, walking on the whole of the underside of the foot. Many mammals, such as cats and dogs, are digitigrade, walking on their toes, the greater stride length allowing more speed. Some animals such as horses are unguligrade, walking on the tips of their toes. This even further increases their stride length and thus their speed. A few mammals, namely the great apes, are also known to walk on their knuckles, at least for their front legs. Giant anteaters and platypuses are also knuckle-walkers. Some mammals are bipeds, using only two limbs for locomotion, which can be seen in, for example, humans and the great apes. Bipedal species have a larger field of vision than quadrupeds, conserve more energy and have the ability to manipulate objects with their hands, which aids in foraging. Instead of walking, some bipeds hop, such as kangaroos and kangaroo rats. Animals will use different gaits for different speeds, terrain and situations. For example, horses show four natural gaits, the slowest horse gait is the walk, then there are three faster gaits which, from slowest to fastest, are the trot, the canter and the gallop. Animals may also have unusual gaits that are used occasionally, such as for moving sideways or backwards. For example, the main human gaits are bipedal walking and running, but they employ many other gaits occasionally, including a four-legged crawl in tight spaces. Mammals show a vast range of gaits, the order that they place and lift their appendages in locomotion.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.

Is SR9009 approved for human use?

No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.

Why is SR9009 banned in sport?

The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.

How should SR9009 be stored?

Research-grade SR9009 is typically stored frozen at about minus twenty degrees Celsius, protected from light and moisture. Stock solutions are often kept in aliquots to avoid repeated freeze-thaw cycles. Specific storage conditions should follow the supplier's documentation.

Network